Listed

Adma Biologics, Inc.

ADMANasdaqCIK 1368514HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$124.4mRevenue, Q2 FY2026, three months to 2026-06-30$124.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$124.4mRevenue, Q2 FY2026, three months to 2026-06-30$124.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure+2.0% on a year earlier
  • Gross margin69.4%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $86.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $124.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure+14.2 pts on a year earlier
  • Operating margin42.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $52.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $124.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure+7.1 pts on a year earlier
  • Net margin30.4%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $37.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $124.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure+2.4 pts on a year earlier
  • Diluted EPS$0.16Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure+14.3% on a year earlier
  • Free cash flow$27.3mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $29.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001140361-26-031445. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001140361-26-031445. Derived: 6-month figure less the 3-month figure.Report this figure+45.8% on a year earlier

Last eight quarters

Full statements
Revenue$124.4mGross margin 69.4%
Diluted EPS$0.16, Q2 FY2026
Free cash flow$27.3m, Q2 FY2026
Adma Biologics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m120Revenue, Q3 FY2024, three months to 2024-09-30$119.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Report this figure118Revenue, Q4 FY2024, three months to 2024-12-31$117.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Report this figure115Revenue, Q1 FY2025, three months to 2025-03-31$114.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure122Revenue, Q2 FY2025, three months to 2025-06-30$122.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure134Revenue, Q3 FY2025, three months to 2025-09-30$134.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Report this figure139Revenue, Q4 FY2025, three months to 2025-12-31$139.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Report this figure114Revenue, Q1 FY2026, three months to 2026-03-31$114.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure124Revenue, Q2 FY2026, three months to 2026-06-30$124.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure
Gross margin%49.8%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $59.7m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Revenue: $119.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Report this figure53.9%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $63.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Revenue: $117.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Report this figure53.2%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $61.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Revenue: $114.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure55.1%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $67.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $122.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure56.3%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $75.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Revenue: $134.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Report this figure63.8%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $88.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Revenue: $139.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Report this figure70.5%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $80.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Revenue: $114.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure69.4%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $86.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $124.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure
Operating margin%33.1%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $39.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Revenue: $119.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Report this figure32.6%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $38.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Revenue: $117.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Report this figure30.4%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $34.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Revenue: $114.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure35.1%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $42.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $122.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure38.0%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $51.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Revenue: $134.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Report this figure45.1%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $62.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Revenue: $139.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Report this figure50.9%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $58.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Revenue: $114.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure42.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $52.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $124.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure
Net margin%30.0%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $35.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Revenue: $119.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Report this figure95.2%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $111.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Revenue: $117.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Report this figure23.4%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $26.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $114.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure28.1%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $34.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $122.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure27.1%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $36.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Revenue: $134.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Report this figure35.5%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $49.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Revenue: $139.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Report this figure39.6%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $45.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $114.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure30.4%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $37.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Revenue: $124.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure
Diluted EPS$ per share0.15Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Report this figurenot reported (Diluted EPS not reported)0.11Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure0.14Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure0.15Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001140361-25-040578.Report this figurenot reported (Diluted EPS not reported)0.19Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure0.16Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001140361-26-031445.Report this figure
Free cash flow$m24.0Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $25.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001140361-25-040578. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001140361-25-040578. Derived: 9-month figure less the 6-month figure.Report this figure47.5Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $50.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Capital expenditure: $2.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Report this figure(24.4)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$19.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Capital expenditure: $4.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure18.7Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $21.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001140361-26-031445. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001140361-26-031445. Derived: 6-month figure less the 3-month figure.Report this figure(1.1)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $13.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001140361-25-040578. Derived: 9-month figure less the 6-month figure.Capital expenditure: $14.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001140361-25-040578. Derived: 9-month figure less the 6-month figure.Report this figure34.6Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $35.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001140361-26-006815. Derived: 12-month figure less the 9-month figure.Report this figure55.7Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $58.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Capital expenditure: $2.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001140361-26-019336.Report this figure27.3Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $29.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001140361-26-031445. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001140361-26-031445. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$510.2mGross margin 57.4%
Diluted EPS$0.60, FY2025
Free cash flow$27.8m, FY2025
Adma Biologics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m80.9Revenue, FY2021, twelve months to 2021-12-31$80.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-28, accession 0001140361-24-010147.Report this figure154Revenue, FY2022, twelve months to 2022-12-31$154.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001140361-25-009257.Report this figure258Revenue, FY2023, twelve months to 2023-12-31$258.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure426Revenue, FY2024, twelve months to 2024-12-31$426.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure510Revenue, FY2025, twelve months to 2025-12-31$510.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure
Gross margin%1.4%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $1.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-02-28, accession 0001140361-24-010147.Revenue: $80.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-28, accession 0001140361-24-010147.Report this figure22.9%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $35.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-03-18, accession 0001140361-25-009257.Revenue: $154.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001140361-25-009257.Report this figure34.4%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $88.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-25, accession 0001140361-26-006815.Revenue: $258.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure51.5%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $219.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-25, accession 0001140361-26-006815.Revenue: $426.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure57.4%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $292.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-25, accession 0001140361-26-006815.Revenue: $510.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure
Operating margin%(72.1%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$58.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-28, accession 0001140361-24-010147.Revenue: $80.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-28, accession 0001140361-24-010147.Report this figure(25.5%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$39.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-18, accession 0001140361-25-009257.Revenue: $154.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001140361-25-009257.Report this figure8.4%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $21.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001140361-26-006815.Revenue: $258.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure32.6%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $139.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001140361-26-006815.Revenue: $426.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure37.5%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $191.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001140361-26-006815.Revenue: $510.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure
Net margin%(88.5%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$71.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-28, accession 0001140361-24-010147.Revenue: $80.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-28, accession 0001140361-24-010147.Report this figure(42.8%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$65.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-18, accession 0001140361-25-009257.Revenue: $154.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001140361-25-009257.Report this figure(10.9%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$28.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001140361-26-006815.Revenue: $258.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure46.4%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $197.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001140361-26-006815.Revenue: $426.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure28.8%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $146.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001140361-26-006815.Revenue: $510.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure
Diluted EPS$ per share(0.51)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-28, accession 0001140361-24-010147.Report this figure(0.33)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-18, accession 0001140361-25-009257.Report this figure(0.13)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure0.81Diluted EPS, FY2024, twelve months to 2024-12-31$0.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure0.60Diluted EPS, FY2025, twelve months to 2025-12-31$0.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure
Free cash flow$m(126)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$112.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-28, accession 0001140361-24-010147.Capital expenditure: $13.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-28, accession 0001140361-24-010147.Report this figure(73.4)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$59.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-18, accession 0001140361-25-009257.Capital expenditure: $13.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-18, accession 0001140361-25-009257.Report this figure4.0Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $8.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001140361-26-006815.Capital expenditure: $4.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure110Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $118.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001140361-26-006815.Capital expenditure: $8.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure27.8Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $50.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001140361-26-006815.Capital expenditure: $22.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001140361-26-006815.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Adma Biologics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$321.0m38,355,684Added+1,524,910
STATE STREET CORP2026-06-30$143.3m17,116,022Added+3,031,817
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$84.6m10,103,809Reduced−203,062
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$84.4m10,088,490Added+1,219,833
Rubric Capital Management LP2026-06-30$78.2m9,339,414Added+7,530,006
Capital Research Global Investors2026-06-30$73.3m8,756,374Reduced−2,434,742
FIRST TRUST ADVISORS LP2026-06-30$65.3m7,798,351Added+7,438,134
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$50.7m6,059,984Added+235,868
Caligan Partners LP2026-06-30$47.9m5,725,007Added+968,496
D. E. Shaw & Co., Inc.2026-06-30$44.1m5,274,597Added+4,713,770

Recent filings

All 970 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Adma Biologics, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0517:16 ET10-QQuarterly reportPeriod 2026-06-300001140361-26-031445
2026-08-0516:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001140361-26-031423
2026-06-0216:05 ET8-K5.07 Shareholder vote results0001140361-26-023705
2026-05-0617:16 ET10-QQuarterly reportPeriod 2026-03-310001140361-26-019336
2026-05-0616:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001140361-26-019295
2026-05-0407:05 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001140361-26-018667
2026-04-1516:30 ETDEF 14AProxy statementPeriod 2026-06-020001140361-26-014799
2026-03-2707:05 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001140361-26-011569
2026-03-0207:05 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001140361-26-007230
2026-02-2517:16 ET10-KAnnual reportPeriod 2025-12-310001140361-26-006815

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 25, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1368514
Tickers
ADMA
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
R&R ACQUISITION VI, INC (to 2012-02-21)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. Listed shows no prices and gives no investment advice.